AstraZeneca: Lynparza shows promise in breast cancer
(CercleFinance.com) - AstraZeneca reports that updated results from a phase III trial showed that Lynparza (olaparib) delivered 'durable and clinically meaningful improvements' in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) at six years for patients with high-risk early breast cancer with HER2-negative germline BRCA mutation (gBRCAm).
These results were presented today at the San Antonio Breast Cancer Symposium 2024 (SABCS) and build on positive primary results published in the New England Journal of Medicine.
At a median follow-up of 6.1 years, Lynparza reduced the risk of death by 28% (HR 0.72) and of invasive cancer recurrence or death by 35% (HR 0.65) compared with placebo.
The benefits of Lynparza were consistent across all key subgroups, including patients with high-risk, hormone-receptor-positive disease.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
These results were presented today at the San Antonio Breast Cancer Symposium 2024 (SABCS) and build on positive primary results published in the New England Journal of Medicine.
At a median follow-up of 6.1 years, Lynparza reduced the risk of death by 28% (HR 0.72) and of invasive cancer recurrence or death by 35% (HR 0.65) compared with placebo.
The benefits of Lynparza were consistent across all key subgroups, including patients with high-risk, hormone-receptor-positive disease.
Copyright (c) 2024 CercleFinance.com. All rights reserved.